lansoprazole has been researched along with Stomach Ulcer in 182 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Stomach Ulcer: Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD." | 9.41 | Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023) |
| "Vonoprazan might not be superior to lansoprazole in the healing of artificial gastric ulcer after ESD." | 9.41 | Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. ( Fujiki, S; Gotoda, T; Ishiguro, M; Kawai, D; Kono, Y; Okanoue, S; Takemoto, K; Takenaka, R; Tsugeno, H, 2021) |
| "To assess whether tegoprazan is non-inferior to lansoprazole in terms of efficacy and safety in patients with gastric ulcers." | 9.34 | Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. ( Baik, GH; Cha, JM; Cheon, GJ; Cho, KB; Cho, YK; Choi, MG; Choi, SC; Jang, JS; Jung, HK; Kang, DH; Kim, AR; Kim, BW; Kim, EJ; Kim, KO; Kim, SK; Kim, TO; Lee, KM; Lee, ST; Lim, YJ; Moon, JS; Park, HW; Park, JJ; Park, SH; Son, BK; Song, GS, 2020) |
| "Vonoprazan efficaciously reduced the delayed bleeding rate in patients with an ESD-induced gastric ulcer." | 9.30 | Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. ( Akasaka, T; Arao, M; Fukui, K; Hamada, K; Hanaoka, N; Higashino, K; Iishi, H; Ishihara, R; Iwatsubo, T; Kanesaka, T; Kato, M; Matsuura, N; Nakahira, H; Okada, H; Shichijo, S; Shimokawa, T; Suzuki, S; Takeuchi, Y; Tonai, Y; Uedo, N; Yamamoto, S; Yamasaki, Y, 2019) |
| " lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU)." | 9.24 | Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. ( Miwa, H; Mori, Y; Nishimura, A; Sakaki, N; Sakurai, Y; Takanami, Y; Tatsumi, T; Uedo, N; Watari, J, 2017) |
| " In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers." | 9.20 | The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study. ( Ahn, JY; Chang, SK; Choi, CH; Han, SB; Kim, JW; Lee, JW; Park, SJ, 2015) |
| " We compared efficacy between 4 and 8 weeks of lansoprazole treatment for iatrogenic gastric ulcers that developed after ESD." | 9.19 | Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study. ( Baek, EK; Chang, SK; Choi, CH; Kim, BJ; Kim, JG; Kim, JW; Lee, KH; Park, JH, 2014) |
| "Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief in such diseases as rheumatoid arthritis, osteoarthritis, and low back pain." | 9.16 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Asaka, M; Ashida, K; Hiraishi, H; Hiramatsu, N; Kanto, T; Katsuo, S; Kontani, T; Matsui, S; Mizokami, Y; Sakaki, N; Soen, S; Sugano, K; Takei, Y; Takeuchi, T, 2012) |
| "The efficacy of low-dose lansoprazole has not been established for the prevention of recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection." | 9.15 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Abe, S; Ashida, K; Chiba, T; Hiramatsu, N; Itabashi, T; Kanto, T; Matsui, S; Matsumoto, Y; Mizokami, Y; Sakaki, N; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2011) |
| "In patients who require continuous treatment with NSAIDs, lansoprazole is superior to ranitidine for healing of NSAID-associated gastric ulcers." | 9.09 | Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. ( Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA, 2000) |
| "To clarify whether the depth of ulceration evaluated by endoscopic ultrasonography (EUS) influences a modified dual therapy with amoxicillin and lansoprazole for the treatment of Helicobacter pylori-positive patients with gastric ulcer." | 9.09 | Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer? ( Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H, 2000) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 9.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 9.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "We studied the action on acid secretion of lansoprazole compared with famotidine by 24-h intragastric pH monitoring, evaluated its clinical effects prospectively, and assessed the importance of acid inhibition in gastric ulcer patients." | 9.08 | Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. ( Ashida, K; Katsu, K; Miyoshi, H; Sakaguchi, M; Umegaki, E, 1995) |
| "To compare the efficacy of lansoprazole and famotidine in the treatment of gastric ulcer, 24 patients with gastric ulcer were treated for 8 weeks." | 9.08 | Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. ( Motoo, Y; Okai, T; Sawabu, N; Songür, Y; Watanabe, H, 1995) |
| "The effects of lansoprazole (30 mg/day) in 18 patients with gastric ulcers and the quality of ulcer healing were studied using endoscopy (including dye endoscopy) and endoscopic ultrasonography (EUS)." | 9.08 | Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings. ( Ajima, H; Ejiri, Y; Ishihata, R; Kasukawa, R; Kondo, Y; Kuwana, T; Mukai, S; Obara, K; Okubo, Y; Yokogi, K, 1995) |
| "The effect of lansoprazole, a new benzimidazole proton pump inhibitor, on the relationship between ulcer healing and changes in mucin content was studied in gastric ulcer patients." | 9.08 | Effects of lansoprazole on gastric ulcer healing and mucin content. ( Ishii, K; Komuro, Y; Miyake, Y; Oida, M; Saigenji, K; Tanabe, S, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 9.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "A multicenter, double-blind study was conducted in 268 patients to compare the safety and efficacy of 15, 30, and 60 mg of lansoprazole and placebo in the treatment of gastric ulcer." | 9.08 | Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. ( Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ, 1995) |
| "The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively." | 9.08 | A trial of lansoprazole in refractory gastric ulcer. ( Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ, 1996) |
| "Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer." | 9.08 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1998) |
| " pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks." | 9.08 | Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H, 1998) |
| "The effects of trimebutine maleate (TM), a prokinetic drug, on gastrointestinal motility in patients with gastric ulcer were investigated." | 9.08 | Effects of trimebutine maleate on gastric motility in patients with gastric ulcer. ( Andou, T; Fujinami, T; Hara, M; Hirako, M; Kamiya, T; Kobayashi, Y; Misu, N; Nagao, T, 1998) |
| "We compared the efficacy and short-term safety of lansoprazole against ranitidine in the healing of gastric ulcer." | 9.07 | Rapid healing of gastric ulcers with lansoprazole. ( Ahlberg, J; Bardhan, KD; Hislop, WS; Lindholmer, C; Long, RG; Morgan, AG; Sjostedt, S; Smith, PM; Stig, R; Wormsley, KG, 1994) |
| "We studied the effectiveness of lansoprazole and ranitidine in promoting gastric ulcer healing in a multicentre double-blind trial, by comparing the proportion of healed ulcers after 4 and 8 weeks of treatment." | 9.07 | Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial. ( Bigard, MA; Bommelaer, G; Colin, R; Dupas, JL; Lemaire, M; Michel, P; Rambaud, JC; Verwaerd, JC, 1994) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 9.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 8.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| "The aim of this study was to comparatively investigate the potential gastroprotective effect and underlying mechanisms of coptisine free base (CFB, 8-hydroxy-7, 8-dihydrocoptisine), berberine and lansoprazole against indomethacin-induced gastric ulcer in rats." | 7.88 | Protective effect of coptisine free base on indomethacin-induced gastric ulcers in rats: Characterization of potential molecular mechanisms. ( Chen, H; Lai, X; Li, C; Lin, G; Luo, C; Su, Z; Tan, L; Wang, Y; Xie, J; Zeng, H, 2018) |
| "The aim of this study was to develop nanoparticles for oral delivery of an acid-labile drug, lansoprazole (LPZ), for gastric ulcer therapy." | 7.81 | Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations. ( Alai, M; Lin, WJ, 2015) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 7.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "Subcutaneous administration of leptin, two PPIs lansoprazole and omeprazole or H(2)-receptor antagonist ranitidine 30 min before AE or Indo produced a dose-dependent and reproducible inhibition of gastric ulcers (GUs)." | 7.73 | Mechanisms of action of leptin in preventing gastric ulcer. ( Adem, A; Adeyemi, EO; Bastaki, SA; Chandranath, IS; Fahim, M; Hasan, MY, 2005) |
| "To describe a case of thrombocytopenia associated with the administration of lansoprazole." | 7.71 | Lansoprazole-induced thrombocytopenia. ( Anderson, CG; Zlabek, JA, 2002) |
| " The optimal dosage and duration of treatment need to be specified." | 6.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "When healing of gastric ulcers is observed using an electronic endoscope with a magnifying function, five types of regenerated mucosa can be distinguished." | 6.68 | Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function. ( Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD." | 5.41 | Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023) |
| "Vonoprazan might not be superior to lansoprazole in the healing of artificial gastric ulcer after ESD." | 5.41 | Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. ( Fujiki, S; Gotoda, T; Ishiguro, M; Kawai, D; Kono, Y; Okanoue, S; Takemoto, K; Takenaka, R; Tsugeno, H, 2021) |
| "To assess whether tegoprazan is non-inferior to lansoprazole in terms of efficacy and safety in patients with gastric ulcers." | 5.34 | Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. ( Baik, GH; Cha, JM; Cheon, GJ; Cho, KB; Cho, YK; Choi, MG; Choi, SC; Jang, JS; Jung, HK; Kang, DH; Kim, AR; Kim, BW; Kim, EJ; Kim, KO; Kim, SK; Kim, TO; Lee, KM; Lee, ST; Lim, YJ; Moon, JS; Park, HW; Park, JJ; Park, SH; Son, BK; Song, GS, 2020) |
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| " Dose-response studies on gastroprotection in stress and indomethacin-induced ulcer and inhibition of pylorus ligation-induced acid secretion indicate that omeprazole significantly blocks gastric lesions at lower dose (2." | 5.32 | A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. ( Ali, E; Bandyopadhyay, U; Banerjee, RK; Biswas, K; Chattopadhyay, I; Varadaraj, A, 2003) |
| "Vonoprazan efficaciously reduced the delayed bleeding rate in patients with an ESD-induced gastric ulcer." | 5.30 | Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. ( Akasaka, T; Arao, M; Fukui, K; Hamada, K; Hanaoka, N; Higashino, K; Iishi, H; Ishihara, R; Iwatsubo, T; Kanesaka, T; Kato, M; Matsuura, N; Nakahira, H; Okada, H; Shichijo, S; Shimokawa, T; Suzuki, S; Takeuchi, Y; Tonai, Y; Uedo, N; Yamamoto, S; Yamasaki, Y, 2019) |
| " Chronic administration of hydrocortisone sodium phosphate resulted in a significant delay of ulcer healing induced by acetic acid." | 5.28 | Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. ( Eastwood, GL; Kuwayama, H; Matsuo, Y, 1991) |
| " lansoprazole, a proton pump inhibitor, for treatment of gastric ulcer (GU) or duodenal ulcer (DU)." | 5.24 | Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. ( Miwa, H; Mori, Y; Nishimura, A; Sakaki, N; Sakurai, Y; Takanami, Y; Tatsumi, T; Uedo, N; Watari, J, 2017) |
| " In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers." | 5.20 | The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study. ( Ahn, JY; Chang, SK; Choi, CH; Han, SB; Kim, JW; Lee, JW; Park, SJ, 2015) |
| " We compared efficacy between 4 and 8 weeks of lansoprazole treatment for iatrogenic gastric ulcers that developed after ESD." | 5.19 | Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study. ( Baek, EK; Chang, SK; Choi, CH; Kim, BJ; Kim, JG; Kim, JW; Lee, KH; Park, JH, 2014) |
| "Low-dose lansoprazole has not been intensively evaluated for its efficacy in the prevention of recurrent gastric or duodenal ulcers in patients receiving long-term non-steroidal anti-inflammatory drug (NSAID) therapy for pain relief in such diseases as rheumatoid arthritis, osteoarthritis, and low back pain." | 5.16 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Asaka, M; Ashida, K; Hiraishi, H; Hiramatsu, N; Kanto, T; Katsuo, S; Kontani, T; Matsui, S; Mizokami, Y; Sakaki, N; Soen, S; Sugano, K; Takei, Y; Takeuchi, T, 2012) |
| "The efficacy of low-dose lansoprazole has not been established for the prevention of recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection." | 5.15 | Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. ( Abe, S; Ashida, K; Chiba, T; Hiramatsu, N; Itabashi, T; Kanto, T; Matsui, S; Matsumoto, Y; Mizokami, Y; Sakaki, N; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2011) |
| "Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily." | 5.12 | Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007) |
| "This analysis compared the efficacy of misoprostol, lansoprazole, and placebo in reducing the risk of gastric or duodenal ulcer recurrence in patients taking NSAIDs and low-dose aspirin." | 5.11 | Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. ( Amer, F; Christopoulos, NG; Goldstein, JL; Huang, B, 2004) |
| "Patients receiving lansoprazole (15 or 30 mg) remained free from gastric ulcer longer than those who received placebo (P<." | 5.10 | Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. ( Agrawal, NM; Campbell, DR; Collis, C; Graham, DY; Haber, MM; Huang, B; Lukasik, NL, 2002) |
| "In patients who require continuous treatment with NSAIDs, lansoprazole is superior to ranitidine for healing of NSAID-associated gastric ulcers." | 5.09 | Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. ( Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA, 2000) |
| "To clarify whether the depth of ulceration evaluated by endoscopic ultrasonography (EUS) influences a modified dual therapy with amoxicillin and lansoprazole for the treatment of Helicobacter pylori-positive patients with gastric ulcer." | 5.09 | Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer? ( Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H, 2000) |
| " Patients with gastric ulcer (GU) or duodenal ulcer (DU) were enrolled in this study; 583 eligible patients (GU, 325; DU, 258) were administered lansoprazole (30 mg/day for 8 weeks for GU, and the same dosage for 6 weeks for DU) as first-line therapy, and a half dose of H2RA as maintenance therapy for 12 months." | 5.09 | Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. ( Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T, 2000) |
| " pylori) infection is known to affect the gastric microcirculation, and cetraxate is reported to accelerate gastric ulcer healing, possibly by augmenting gastric mucosal blood flow (MBF)." | 5.09 | Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers. ( Adachi, K; Fujishiro, H; Ishihara, S; Kawamura, A; Kazumori, H; Kinoshita, Y; Moriyama, N; Okuyama, T; Sato, H; Suetsugu, H; Watanabe, M, 2001) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 5.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 5.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "We studied the action on acid secretion of lansoprazole compared with famotidine by 24-h intragastric pH monitoring, evaluated its clinical effects prospectively, and assessed the importance of acid inhibition in gastric ulcer patients." | 5.08 | Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. ( Ashida, K; Katsu, K; Miyoshi, H; Sakaguchi, M; Umegaki, E, 1995) |
| "To compare the efficacy of lansoprazole and famotidine in the treatment of gastric ulcer, 24 patients with gastric ulcer were treated for 8 weeks." | 5.08 | Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. ( Motoo, Y; Okai, T; Sawabu, N; Songür, Y; Watanabe, H, 1995) |
| "The effects of lansoprazole (30 mg/day) in 18 patients with gastric ulcers and the quality of ulcer healing were studied using endoscopy (including dye endoscopy) and endoscopic ultrasonography (EUS)." | 5.08 | Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings. ( Ajima, H; Ejiri, Y; Ishihata, R; Kasukawa, R; Kondo, Y; Kuwana, T; Mukai, S; Obara, K; Okubo, Y; Yokogi, K, 1995) |
| "The effect of lansoprazole, a new benzimidazole proton pump inhibitor, on the relationship between ulcer healing and changes in mucin content was studied in gastric ulcer patients." | 5.08 | Effects of lansoprazole on gastric ulcer healing and mucin content. ( Ishii, K; Komuro, Y; Miyake, Y; Oida, M; Saigenji, K; Tanabe, S, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 5.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "A multicenter, double-blind study was conducted in 268 patients to compare the safety and efficacy of 15, 30, and 60 mg of lansoprazole and placebo in the treatment of gastric ulcer." | 5.08 | Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. ( Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ, 1995) |
| "The purpose of this study was to clarify the effect of lansoprazole on basic fibroblast growth factor (bFGF) during the healing of gastric ulcers in comparison with famotidine and rebamipide." | 5.08 | Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. ( Akiba, Y; Inoue, J; Ishii, H; Ito, T; Nakamura, M; Oda, M; Tsuchiya, M, 1995) |
| "The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively." | 5.08 | A trial of lansoprazole in refractory gastric ulcer. ( Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ, 1996) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| "Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer." | 5.08 | Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1998) |
| " pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks." | 5.08 | Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H, 1998) |
| "The effects of trimebutine maleate (TM), a prokinetic drug, on gastrointestinal motility in patients with gastric ulcer were investigated." | 5.08 | Effects of trimebutine maleate on gastric motility in patients with gastric ulcer. ( Andou, T; Fujinami, T; Hara, M; Hirako, M; Kamiya, T; Kobayashi, Y; Misu, N; Nagao, T, 1998) |
| "We compared the efficacy and short-term safety of lansoprazole against ranitidine in the healing of gastric ulcer." | 5.07 | Rapid healing of gastric ulcers with lansoprazole. ( Ahlberg, J; Bardhan, KD; Hislop, WS; Lindholmer, C; Long, RG; Morgan, AG; Sjostedt, S; Smith, PM; Stig, R; Wormsley, KG, 1994) |
| "We studied the effectiveness of lansoprazole and ranitidine in promoting gastric ulcer healing in a multicentre double-blind trial, by comparing the proportion of healed ulcers after 4 and 8 weeks of treatment." | 5.07 | Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial. ( Bigard, MA; Bommelaer, G; Colin, R; Dupas, JL; Lemaire, M; Michel, P; Rambaud, JC; Verwaerd, JC, 1994) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 5.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " Double-blind comparative studies with a beta-blocker, famotidine, in gastric ulcer (study 1) and in duodenal ulcer (study 2) were conducted." | 5.07 | [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer]. ( Ogawa, N, 1992) |
| "The proton pump inhibitors (PPIs) lansoprazole (LPZ) and omeprazole (OPZ) have been widely used for more than 20 years in the treatment of acid-related diseases such as gastro-duodenal ulcers and reflux esophagitis." | 4.89 | Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. ( Satoh, H, 2013) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 4.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| " trimera (EOBT) against gastric ulcer lesions caused by absolute ethanol and acetic acid, respectively, and to identify the mechanism of action of this essential oil in male Wistar rats." | 4.02 | The essential oil from Baccharis trimera (Less.) DC improves gastric ulcer healing in rats through modulation of VEGF and MMP-2 activity. ( Assunção, R; Besten, MA; Bueno, G; Chavez Rico, SL; Emílio-Silva, MT; Heiden, G; Hiruma-Lima, CA; Justulin, LA; Lima Camargo, AC; Machado da Rocha, LR; Nunes, DS; Ohara, R; Périco, LL; Rodrigues, VP, 2021) |
| "The aim of this study was to comparatively investigate the potential gastroprotective effect and underlying mechanisms of coptisine free base (CFB, 8-hydroxy-7, 8-dihydrocoptisine), berberine and lansoprazole against indomethacin-induced gastric ulcer in rats." | 3.88 | Protective effect of coptisine free base on indomethacin-induced gastric ulcers in rats: Characterization of potential molecular mechanisms. ( Chen, H; Lai, X; Li, C; Lin, G; Luo, C; Su, Z; Tan, L; Wang, Y; Xie, J; Zeng, H, 2018) |
| "The aim of this study was to develop nanoparticles for oral delivery of an acid-labile drug, lansoprazole (LPZ), for gastric ulcer therapy." | 3.81 | Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations. ( Alai, M; Lin, WJ, 2015) |
| " The pharmacological activity of AFE and pure scopoletin at the same equivalent dose present in AFE was investigated in rat on gastro-esophageal inflammatory models (acid reflux esophagitis, acute gastritis induced by ethanol and serotonin, and chronic gastric ulcer induced by acetic acid); gastric biochemical parameters and gastrointestinal motility." | 3.77 | Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. ( Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W, 2011) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| " Helicobacter pylori-infected patients with gastritis and gastric ulcer received eradication therapy: lansoprazole (60 mg/day), clarithromycin (400 mg/day), and amoxicillin (1500 mg/day) for 1 week." | 3.74 | Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura. ( Arakawa, Y; Hatta, Y; Hayashi, I; Iwamoto, M; Kato, K; Kurihara, R; Kurosaka, H; Matsukawa, Y; Mizuno, S; Sawada, S, 2007) |
| "Subcutaneous administration of leptin, two PPIs lansoprazole and omeprazole or H(2)-receptor antagonist ranitidine 30 min before AE or Indo produced a dose-dependent and reproducible inhibition of gastric ulcers (GUs)." | 3.73 | Mechanisms of action of leptin in preventing gastric ulcer. ( Adem, A; Adeyemi, EO; Bastaki, SA; Chandranath, IS; Fahim, M; Hasan, MY, 2005) |
| " pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid." | 3.72 | Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003) |
| " In the present study, we investigated the protective effects of these compounds against gastric ulcers induced by acidified ethanol (AE) and indomethacin." | 3.71 | A comparative study on the activity of lansoprazole, omeprazole and PD-136450 on acidified ethanol- and indomethacin-induced gastric lesions in the rat. ( Bastaki, SM; Chandranath, SI; Singh, J, 2002) |
| "To describe a case of thrombocytopenia associated with the administration of lansoprazole." | 3.71 | Lansoprazole-induced thrombocytopenia. ( Anderson, CG; Zlabek, JA, 2002) |
| "The gastroprotective effect of the triterpene oleanolic acid (OA) was assessed on gastric ulceration in rats." | 3.71 | Gastroprotective activity of oleanolic acid derivatives on experimentally induced gastric lesions in rats and mice. ( Astudillo, L; Rodriguez, JA; Schmeda-Hirschmann, G, 2002) |
| "Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H." | 3.70 | Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998) |
| "To evaluate endogenous and exogenous factors affecting the quality of ulcer healing produced by proton pump inhibitors, gastric acid pH, serum gastrin, and serum pepsinogen (PG) I and II were measured in peptic ulcer patients before and after treatment with lansoprazole 30 mg once daily." | 3.69 | Factors affecting quality of ulcer healing after lansoprazole treatment. ( Hanai, H; Ito, G; Kaneko, E; Nakagawara, M; Nawano, M; Ooi, S; Watanabe, F, 1995) |
| "We studied the detailed surface structure and changes in the regenerated mucosa during the course of healing of recurrent gastric ulcers treated with lansoprazole or famotidine, using a magnifying electronic endoscope (videoendoscope) and a dye contrast method." | 3.69 | Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy. ( Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T, 1995) |
| "pylori-positive early gastric cancer or gastric adenoma underwent endoscopic resection and were randomly allocated to eradication or placebo group in a prospective, double-blinded, and placebo-controlled manner." | 2.78 | Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial. ( Cho, WY; Choi, IJ; Jung, HC; Keum, B; Kim, JG; Kim, SG; Lee, JH; Lee, YC; Park, BJ; Park, SK; Song, HJ, 2013) |
| "While proton pump inhibitors are frequently administered in the intensive care unit, the pharmacodynamic response of acid suppression between the enteral and intravenous (IV) route is unknown." | 2.73 | Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients. ( Devlin, JW; Olsen, KM, 2008) |
| " The optimal dosage and duration of treatment need to be specified." | 2.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies." | 2.68 | Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. ( Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I, 1995) |
| "When healing of gastric ulcers is observed using an electronic endoscope with a magnifying function, five types of regenerated mucosa can be distinguished." | 2.68 | Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function. ( Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "pylori infection and the ulcer recurrence rate after 1 year were investigated." | 2.68 | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Lansoprazole is a benzimidazole derivative that effectively decreases gastric acid secretion, regardless of the primary stimulus, via inhibition of gastric H+,K(+)-adenosine triphosphatase (ATPase)." | 2.39 | Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. ( Faulds, D; Spencer, CM, 1994) |
| "Lansoprazole, one of PPIs, is a strong antacid and it cures stomach and duodenal ulcers at early stages as well as having antibiotic action towards HP." | 2.38 | [Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy]. ( Kawano, S; Murai, M; Tamura, K; Tanaka, M, 1993) |
| "Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that is currently considered as a potential alternative to proton pump inhibitors (PPIs) for the treatment of acid-related diseases." | 1.48 | Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis. ( Fushimi, S; Horikawa, Y; Kato, Y; Mimori, N; Mizutamari, H; Okubo, S; Sato, S, 2018) |
| "Stress gastric ulcer is a serious complication, but the mechanism involved is not fully clarified." | 1.33 | Endoplasmic reticulum stress response is involved in the pathogenesis of stress induced gastric lesions in rats. ( Chen, L; Geng, B; Ke, Y; Lou, LX; Pan, CS; Qi, YF; Tang, CS; Wang, X; Yu, F; Zhang, J, 2006) |
| " Dose-response studies on gastroprotection in stress and indomethacin-induced ulcer and inhibition of pylorus ligation-induced acid secretion indicate that omeprazole significantly blocks gastric lesions at lower dose (2." | 1.32 | A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. ( Ali, E; Bandyopadhyay, U; Banerjee, RK; Biswas, K; Chattopadhyay, I; Varadaraj, A, 2003) |
| "Pretreatment with lansoprazole 90 micromol/kg, given intraduodenally as single dose or once daily by intragastric route for 8 days, significantly prevented ethanol-HCl-induced gastric damage." | 1.32 | Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. ( Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Lazzeri, G; Lubrano, V; Natale, G; Vassalle, C, 2004) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| " Chronic administration of hydrocortisone sodium phosphate resulted in a significant delay of ulcer healing induced by acetic acid." | 1.28 | Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. ( Eastwood, GL; Kuwayama, H; Matsuo, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 81 (44.51) | 18.2507 |
| 2000's | 57 (31.32) | 29.6817 |
| 2010's | 36 (19.78) | 24.3611 |
| 2020's | 8 (4.40) | 2.80 |
| Authors | Studies |
|---|---|
| Parra, T | 1 |
| Benites, J | 1 |
| Ruiz, LM | 1 |
| Sepulveda, B | 4 |
| Simirgiotis, M | 3 |
| Areche, C | 4 |
| Quispe, C | 2 |
| García-Beltrán, O | 2 |
| Torres-Benítez, A | 1 |
| Reyes-Ortíz, J | 1 |
| Miao, T | 1 |
| Zhang, Y | 1 |
| Bai, L | 1 |
| Yang, X | 1 |
| Wen, X | 1 |
| Gao, N | 2 |
| Yan, S | 2 |
| Chen, B | 2 |
| Satoh, H | 4 |
| Akiba, Y | 3 |
| Urushidani, T | 1 |
| Cho, YK | 1 |
| Choi, MG | 1 |
| Choi, SC | 1 |
| Lee, KM | 1 |
| Kim, TO | 1 |
| Park, SH | 2 |
| Moon, JS | 1 |
| Lim, YJ | 1 |
| Kang, DH | 1 |
| Cheon, GJ | 1 |
| Baik, GH | 1 |
| Kim, KO | 1 |
| Cho, KB | 1 |
| Jang, JS | 1 |
| Park, JJ | 1 |
| Son, BK | 1 |
| Jung, HK | 1 |
| Kim, BW | 1 |
| Kim, SK | 1 |
| Lee, ST | 1 |
| Cha, JM | 1 |
| Kim, AR | 1 |
| Kim, EJ | 1 |
| Park, HW | 1 |
| Song, GS | 1 |
| Marcus, EA | 1 |
| Pisegna, JR | 1 |
| Bueno, G | 1 |
| Chavez Rico, SL | 1 |
| Périco, LL | 1 |
| Ohara, R | 1 |
| Rodrigues, VP | 1 |
| Emílio-Silva, MT | 1 |
| Assunção, R | 1 |
| Machado da Rocha, LR | 1 |
| Nunes, DS | 1 |
| Besten, MA | 1 |
| Heiden, G | 1 |
| Lima Camargo, AC | 1 |
| Justulin, LA | 1 |
| Hiruma-Lima, CA | 3 |
| Kawai, D | 1 |
| Takenaka, R | 3 |
| Ishiguro, M | 1 |
| Okanoue, S | 1 |
| Gotoda, T | 1 |
| Kono, Y | 1 |
| Takemoto, K | 1 |
| Tsugeno, H | 1 |
| Fujiki, S | 1 |
| Horikawa, Y | 1 |
| Mizutamari, H | 1 |
| Mimori, N | 1 |
| Kato, Y | 1 |
| Fushimi, S | 1 |
| Sato, S | 2 |
| Okubo, S | 1 |
| Luo, C | 1 |
| Chen, H | 1 |
| Wang, Y | 1 |
| Lin, G | 1 |
| Li, C | 1 |
| Tan, L | 1 |
| Su, Z | 1 |
| Lai, X | 1 |
| Xie, J | 1 |
| Zeng, H | 1 |
| Ishido, K | 1 |
| Tanabe, S | 2 |
| Azuma, M | 1 |
| Katada, C | 1 |
| Wada, T | 1 |
| Yano, T | 1 |
| Koizumi, W | 1 |
| Hirai, A | 1 |
| Takeuchi, T | 2 |
| Takahashi, Y | 3 |
| Kawaguchi, S | 1 |
| Ota, K | 1 |
| Harada, S | 1 |
| Kojima, Y | 1 |
| Tominaga, K | 1 |
| Tokioka, S | 1 |
| Higuchi, K | 4 |
| Hamada, K | 1 |
| Uedo, N | 2 |
| Tonai, Y | 1 |
| Arao, M | 1 |
| Suzuki, S | 1 |
| Iwatsubo, T | 1 |
| Kato, M | 3 |
| Shichijo, S | 1 |
| Yamasaki, Y | 1 |
| Matsuura, N | 1 |
| Nakahira, H | 1 |
| Kanesaka, T | 1 |
| Yamamoto, S | 1 |
| Akasaka, T | 1 |
| Hanaoka, N | 1 |
| Takeuchi, Y | 1 |
| Higashino, K | 1 |
| Ishihara, R | 1 |
| Okada, H | 3 |
| Iishi, H | 1 |
| Fukui, K | 2 |
| Shimokawa, T | 1 |
| Yan, B | 1 |
| Lu, Z | 1 |
| Ge, Z | 1 |
| Liu, S | 1 |
| Guo, X | 1 |
| Tian, D | 1 |
| Yang, Y | 2 |
| Li, X | 1 |
| Gong, W | 1 |
| Liu, Z | 1 |
| Liu, M | 1 |
| Zhou, B | 1 |
| Zhao, K | 1 |
| Pan, F | 1 |
| Yang, J | 1 |
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Sakaki, N | 6 |
| Ashida, K | 6 |
| Mizokami, Y | 4 |
| Chiba, T | 3 |
| Matsui, S | 3 |
| Kanto, T | 3 |
| Uemura, N | 2 |
| Hiramatsu, N | 3 |
| Sugano, K | 3 |
| Park, JH | 1 |
| Baek, EK | 1 |
| Choi, CH | 2 |
| Lee, KH | 1 |
| Kim, BJ | 1 |
| Kim, JW | 2 |
| Kim, JG | 2 |
| Chang, SK | 2 |
| Alai, M | 2 |
| Lin, WJ | 2 |
| Ahn, JY | 1 |
| Lee, JW | 1 |
| Park, SJ | 1 |
| Han, SB | 1 |
| Alkeraye, S | 1 |
| Baclet, Y | 1 |
| Delaporte, E | 1 |
| Mizukami, K | 1 |
| Murakami, K | 3 |
| Miwa, H | 1 |
| Watari, J | 1 |
| Mori, Y | 1 |
| Sakurai, Y | 1 |
| Takanami, Y | 1 |
| Nishimura, A | 1 |
| Tatsumi, T | 2 |
| Lin, PY | 1 |
| Tang, JH | 1 |
| Chang, CC | 1 |
| Olsen, KM | 2 |
| Devlin, JW | 1 |
| Cheon, JH | 1 |
| Kim, JH | 1 |
| Lee, SK | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
| Lee, YC | 2 |
| Pellicano, R | 1 |
| Molloy, D | 1 |
| Molloy, A | 1 |
| O'Loughlin, C | 1 |
| Falconer, M | 1 |
| Hennessy, M | 1 |
| Inoue, M | 2 |
| Hori, S | 1 |
| Kawahara, Y | 2 |
| Kawano, S | 6 |
| Toyokawa, T | 1 |
| Onishi, Y | 1 |
| Shiratori, Y | 1 |
| Yamamoto, K | 2 |
| Kobayashi, S | 1 |
| Nakajima, N | 1 |
| Ito, Y | 1 |
| Moriyama, M | 1 |
| Nishino, M | 1 |
| Sugimoto, M | 1 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Uotani, T | 1 |
| Shirai, N | 1 |
| Ikuma, M | 1 |
| Tanaka, T | 3 |
| Sugimura, H | 1 |
| Hishida, A | 1 |
| Furuta, T | 4 |
| Fornai, M | 2 |
| Colucci, R | 2 |
| Antonioli, L | 1 |
| Awwad, O | 1 |
| Ugolini, C | 1 |
| Tuccori, M | 1 |
| Fulceri, F | 1 |
| Natale, G | 2 |
| Basolo, F | 1 |
| Blandizzi, C | 2 |
| Wilcox, CM | 1 |
| Seay, T | 1 |
| Arcury, J | 1 |
| Hirschowitz, BI | 1 |
| Chandranath, SI | 2 |
| Bastaki, SM | 2 |
| D'Souza, A | 1 |
| Adem, A | 2 |
| Singh, J | 2 |
| Mahattanadul, S | 1 |
| Ridtitid, W | 1 |
| Nima, S | 1 |
| Phdoongsombut, N | 1 |
| Ratanasuwon, P | 1 |
| Kasiwong, S | 1 |
| Theoduloz, C | 3 |
| Pertino, MW | 1 |
| Rodríguez, JA | 4 |
| Schmeda-Hirschmann, G | 4 |
| Hori, K | 1 |
| Tanioka, D | 1 |
| Tsuzuki, T | 1 |
| Yagi, S | 1 |
| Matsumoto, Y | 1 |
| Itabashi, T | 1 |
| Abe, S | 1 |
| Shimada, K | 1 |
| Uchiyama, S | 1 |
| Imaeda, H | 1 |
| Hosoe, N | 1 |
| Suzuki, H | 7 |
| Saito, Y | 1 |
| Ida, Y | 1 |
| Nakamura, R | 1 |
| Iwao, Y | 1 |
| Ogata, H | 1 |
| Hibi, T | 4 |
| San-Martín, A | 1 |
| Rovirosa, J | 1 |
| Lee, SH | 2 |
| Lee, CK | 1 |
| Chung, IK | 1 |
| Shim, YS | 1 |
| Lee, TH | 1 |
| Kim, HS | 1 |
| Kim, SJ | 1 |
| Kontani, T | 1 |
| Katsuo, S | 1 |
| Takei, Y | 1 |
| Asaka, M | 8 |
| Soen, S | 1 |
| Hiraishi, H | 2 |
| Okamura, Y | 1 |
| Takeno, S | 1 |
| Moroga, T | 1 |
| Yamashita, S | 1 |
| Kawahara, K | 1 |
| Kim, SG | 1 |
| Song, HJ | 1 |
| Choi, IJ | 1 |
| Cho, WY | 1 |
| Lee, JH | 1 |
| Keum, B | 1 |
| Park, SK | 1 |
| Park, BJ | 1 |
| Jung, HC | 1 |
| Shcherbynina, MB | 1 |
| Ishibashi, S | 1 |
| Iwakiri, R | 1 |
| Shimoda, R | 1 |
| Ootani, H | 1 |
| Kawasaki, S | 1 |
| Tadano, J | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Oda, K | 2 |
| Fujise, T | 1 |
| Yoshida, T | 1 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fujimoto, K | 1 |
| Ota, S | 1 |
| Terano, A | 3 |
| Weaver, AL | 1 |
| Gitlin, N | 1 |
| Sato, R | 1 |
| Okimoto, T | 1 |
| Nasu, M | 1 |
| Fujioka, T | 2 |
| Kodama, M | 1 |
| Kagawa, J | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Tsuji, S | 3 |
| Sun, WH | 1 |
| Tsujii, M | 1 |
| Kawai, N | 1 |
| Kimura, A | 1 |
| Kakiuchi, Y | 1 |
| Yasumaru, S | 1 |
| Komori, M | 1 |
| Murata, H | 1 |
| Sasaki, Y | 1 |
| Hori, M | 1 |
| Biswas, K | 1 |
| Bandyopadhyay, U | 1 |
| Chattopadhyay, I | 1 |
| Varadaraj, A | 1 |
| Ali, E | 1 |
| Banerjee, RK | 1 |
| Fedele, E | 1 |
| Kamiya, T | 2 |
| Kobayashi, Y | 2 |
| Misu, N | 2 |
| Hirako, M | 2 |
| Adachi, H | 1 |
| Nagao, T | 2 |
| Shikano, M | 1 |
| Matsuhisa, E | 1 |
| Ando, T | 1 |
| Kimura, G | 1 |
| Uthaisaengsook, W | 1 |
| Lazzeri, G | 1 |
| Lubrano, V | 1 |
| Vassalle, C | 1 |
| Del Tacca, M | 1 |
| Batista, LM | 1 |
| de Almeida, AB | 2 |
| de Pietro Magri, L | 1 |
| Toma, W | 2 |
| Calvo, TR | 2 |
| Vilegas, W | 2 |
| Souza Brito, AR | 1 |
| Sugiyama, T | 6 |
| Mizuki, A | 1 |
| Tatemichi, M | 1 |
| Nishiya, H | 1 |
| Hayashi, T | 2 |
| Tsukada, N | 1 |
| Nagata, H | 1 |
| Ishii, H | 10 |
| Tiesmeier, J | 1 |
| Hinner, H | 1 |
| Kraus, J | 1 |
| Schuppert, F | 1 |
| Masaoka, T | 2 |
| SuzukiKurabayashi, HK | 1 |
| Kamiya, AG | 1 |
| Goldstein, JL | 2 |
| Huang, B | 3 |
| Amer, F | 2 |
| Christopoulos, NG | 1 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 1 |
| Sipponen, P | 1 |
| Mäkinen, J | 1 |
| Rautelin, H | 1 |
| Färkkilä, M | 1 |
| Sánchez, M | 2 |
| Yáñez, T | 2 |
| Razmilic, I | 2 |
| Si, JM | 1 |
| Cao, Q | 1 |
| Wu, JG | 1 |
| Adeyemi, EO | 1 |
| Bastaki, SA | 1 |
| Chandranath, IS | 1 |
| Hasan, MY | 1 |
| Fahim, M | 1 |
| Bracke, A | 1 |
| Nijsten, T | 1 |
| Vandermaesen, J | 1 |
| Meuleman, L | 1 |
| Lambert, J | 1 |
| Sakai, G | 1 |
| Güliter, S | 1 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Agustí-Escasany, A | 1 |
| Vallano-Ferraz, A | 1 |
| Arakawa, T | 5 |
| Yoshikawa, T | 3 |
| Haruma, K | 2 |
| Shimosegawa, T | 1 |
| Sakamoto, C | 1 |
| Takahashi, S | 1 |
| Kinoshita, Y | 3 |
| Kobayashi, K | 6 |
| Lou, LX | 1 |
| Geng, B | 1 |
| Yu, F | 1 |
| Zhang, J | 1 |
| Pan, CS | 1 |
| Chen, L | 1 |
| Qi, YF | 1 |
| Ke, Y | 1 |
| Wang, X | 1 |
| Tang, CS | 1 |
| Lima, ZP | 1 |
| Silva, JS | 1 |
| Ballesteros, KV | 1 |
| Pellizzon, CH | 1 |
| Tamashiro, J | 1 |
| Brito, AR | 2 |
| Takahira, RK | 1 |
| Matsukawa, Y | 2 |
| Kato, K | 1 |
| Hatta, Y | 1 |
| Iwamoto, M | 1 |
| Mizuno, S | 1 |
| Kurihara, R | 1 |
| Arakawa, Y | 1 |
| Kurosaka, H | 1 |
| Hayashi, I | 1 |
| Sawada, S | 1 |
| Joh, T | 2 |
| Chen, ZM | 1 |
| Shah, R | 1 |
| Zuckerman, GR | 1 |
| Wang, HL | 1 |
| Dengiz, GO | 1 |
| Odabasoglu, F | 1 |
| Halici, Z | 1 |
| Cadirci, E | 1 |
| Suleyman, H | 1 |
| Cryer, B | 1 |
| Hunt, B | 1 |
| Hashiguchi, M | 1 |
| Yamauchi, N | 1 |
| Uchikura, T | 1 |
| Mochizuki, M | 1 |
| Spencer, CM | 1 |
| Faulds, D | 2 |
| Morini, G | 1 |
| Grandi, D | 1 |
| Arcari, ML | 1 |
| Bertaccini, G | 2 |
| Coruzzi, G | 1 |
| Adami, M | 1 |
| Higashi, T | 1 |
| Mukuda, T | 1 |
| Imaizumi, T | 1 |
| Miura, N | 1 |
| Miyajima, K | 1 |
| Fukuda, M | 2 |
| Noguchi, M | 1 |
| Hisano, K | 1 |
| Ochiai, T | 1 |
| Fujita, N | 2 |
| Kobayashi, T | 1 |
| Yabana, T | 1 |
| Kurokawa, I | 1 |
| Yachi, A | 1 |
| Katoh, M | 1 |
| Kudoh, M | 1 |
| Kagaya, H | 3 |
| Katagiri, M | 3 |
| Takeda, H | 3 |
| Futami, H | 3 |
| Arai, H | 3 |
| Hanai, H | 3 |
| Kaneko, E | 5 |
| Takimoto, T | 1 |
| Ido, K | 1 |
| Taniguchi, Y | 1 |
| Satoh, K | 1 |
| Saifuku, K | 1 |
| Kihira, K | 1 |
| Yoshida, Y | 3 |
| Kimura, K | 1 |
| Nakata, H | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Shimoyama, T | 4 |
| Munakata, A | 2 |
| Mizuki, I | 1 |
| Akagi, T | 1 |
| Fukuda, S | 2 |
| Ohkawa, K | 1 |
| Aisawa, T | 1 |
| Sakata, Y | 1 |
| Fukushi, M | 1 |
| Fukuda, Y | 2 |
| Yamamoto, I | 1 |
| Okui, M | 1 |
| Tonokatsu, Y | 1 |
| Otani, Y | 1 |
| Kitajima, M | 1 |
| Sugiyama, M | 1 |
| Watanabe, Y | 1 |
| Aoki, T | 1 |
| Sakaguchi, M | 2 |
| Umegaki, E | 1 |
| Miyoshi, H | 1 |
| Katsu, K | 2 |
| Okai, T | 2 |
| Sawabu, N | 2 |
| Songür, Y | 1 |
| Motoo, Y | 2 |
| Watanabe, H | 3 |
| Obara, K | 1 |
| Kuwana, T | 1 |
| Ishihata, R | 1 |
| Kondo, Y | 1 |
| Ejiri, Y | 1 |
| Yokogi, K | 1 |
| Okubo, Y | 1 |
| Ajima, H | 1 |
| Mukai, S | 1 |
| Kasukawa, R | 1 |
| Tsukamoto, Y | 1 |
| Goto, H | 1 |
| Hase, S | 1 |
| Niwa, Y | 1 |
| Arisawa, T | 1 |
| Hayakawa, T | 1 |
| Yoshikane, H | 1 |
| Komuro, Y | 1 |
| Ishii, K | 1 |
| Miyake, Y | 1 |
| Oida, M | 1 |
| Saigenji, K | 1 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Ueda, F | 1 |
| Suzuki, Y | 1 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 1 |
| Fukuda, T | 2 |
| Shimizu, Y | 1 |
| Ohtani, K | 1 |
| Tamada, F | 1 |
| Hirohata, S | 1 |
| Honsako, Y | 1 |
| Kumada, H | 1 |
| Kashio, Y | 1 |
| Konishi, M | 1 |
| Fujio, Y | 1 |
| Yamamoto, T | 3 |
| Miura, J | 1 |
| Miyamoto, M | 1 |
| Hashimoto, M | 2 |
| Hoshihara, Y | 3 |
| Kimura, T | 2 |
| Iguchi, D | 2 |
| Sugawara, K | 2 |
| Fukuchi, S | 2 |
| Takemoto, T | 3 |
| Asaki, S | 2 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 1 |
| Toyota, T | 1 |
| Tanaka, M | 4 |
| Takiuchi, H | 1 |
| Egashira, Y | 1 |
| Ito, G | 1 |
| Nakagawara, M | 1 |
| Watanabe, F | 1 |
| Ooi, S | 1 |
| Nawano, M | 1 |
| Hoshino, E | 1 |
| Umeda, N | 1 |
| Sano, J | 1 |
| Miki, K | 1 |
| Yahagi, N | 1 |
| Oka, M | 1 |
| Kimura, M | 1 |
| Miyashita, H | 1 |
| Mine, T | 2 |
| Yasuda, H | 1 |
| Akimoto, K | 1 |
| Katoaka, A | 1 |
| Mashima, H | 1 |
| Tajima, A | 1 |
| Fukujin, H | 1 |
| Tsuchida, T | 1 |
| Takano, T | 1 |
| Nagasawa, J | 1 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Aoyama, N | 1 |
| Misaki, F | 1 |
| Himeno, S | 1 |
| Kasuga, M | 1 |
| Ogoshi, K | 1 |
| Kato, T | 2 |
| Sakagawa, T | 1 |
| Ponce, J | 1 |
| Nos, P | 1 |
| Avner, DL | 1 |
| Movva, R | 1 |
| Nelson, KJ | 1 |
| McFarland, M | 1 |
| Berry, W | 1 |
| Erfling, W | 1 |
| Choné, L | 1 |
| Fléjou, JF | 1 |
| Grignon, Y | 1 |
| Bigard, MA | 3 |
| Kohli, Y | 1 |
| Azuma, T | 1 |
| Ito, S | 1 |
| Hirai, M | 1 |
| Michel, P | 2 |
| Duhamel, C | 1 |
| Bazin, B | 1 |
| Raoul, JL | 1 |
| Person, B | 1 |
| Legoux, JL | 1 |
| Sallerin, V | 1 |
| Colin, R | 2 |
| Maruoka, A | 1 |
| Chijiiwa, Y | 1 |
| Nawata, H | 1 |
| Florent, C | 1 |
| Bardhan, KD | 1 |
| Ahlberg, J | 1 |
| Hislop, WS | 1 |
| Lindholmer, C | 1 |
| Long, RG | 1 |
| Morgan, AG | 1 |
| Sjostedt, S | 1 |
| Smith, PM | 1 |
| Stig, R | 1 |
| Wormsley, KG | 1 |
| Lemaire, M | 2 |
| Bommelaer, G | 1 |
| Rambaud, JC | 1 |
| Dupas, JL | 1 |
| Verwaerd, JC | 1 |
| Seifert, E | 1 |
| Tamura, K | 1 |
| Murai, M | 1 |
| Kimura, S | 1 |
| Uchida, T | 1 |
| Brunner, G | 1 |
| Arnold, R | 1 |
| Hennig, U | 1 |
| Fuchs, W | 1 |
| Nakamura, M | 2 |
| Oda, M | 2 |
| Inoue, J | 1 |
| Ito, T | 1 |
| Tsuchiya, M | 1 |
| van Rensburg, CJ | 1 |
| Louw, JA | 1 |
| Girdwood, AH | 1 |
| Simjee, AE | 1 |
| Marks, IN | 1 |
| Kudo, M | 2 |
| Sukegawa, M | 2 |
| Koshiyama, T | 1 |
| Nishikawa, K | 2 |
| Hokari, K | 2 |
| Murakami, M | 1 |
| Saita, H | 2 |
| Baba, S | 2 |
| Suzuki, T | 1 |
| Nonaka, Y | 1 |
| Hirano, M | 1 |
| Nomura, T | 1 |
| Miyazawa, I | 1 |
| Ishikawa, F | 1 |
| Kakiuchi, T | 1 |
| Caselli, M | 1 |
| Trevisani, L | 1 |
| Tursi, A | 1 |
| Sartori, S | 1 |
| Ruina, M | 1 |
| Luzzi, I | 1 |
| Gaudenzi, P | 1 |
| Alvisi, V | 1 |
| Gasbarrini, G | 1 |
| Arroyo Villarino, MT | 1 |
| Lanas Arbeloa, A | 1 |
| Esteva Díaz, F | 1 |
| Ortego Fernández de Retana, J | 1 |
| Sainz Samitier, R | 1 |
| Gupta, VK | 1 |
| Dhar, A | 1 |
| Srinivasan, S | 1 |
| Rattan, A | 1 |
| Sharma, MP | 1 |
| Suzuki, M | 4 |
| Mori, M | 3 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Kovacs, TO | 1 |
| Campbell, D | 1 |
| Haber, M | 1 |
| Rose, P | 1 |
| Jennings, DE | 1 |
| Richter, J | 1 |
| Takashima, M | 1 |
| Kajimura, M | 1 |
| Sakaguchi, AA | 1 |
| Miura, S | 1 |
| Spinzi, GC | 1 |
| Bierti, L | 1 |
| Bortoli, A | 1 |
| Colombo, E | 1 |
| Fertitta, AM | 1 |
| Lanzi, GL | 1 |
| Venturelli, R | 1 |
| Minoli, G | 1 |
| Treiber, G | 1 |
| Lambert, JR | 1 |
| Lamouliatte, H | 1 |
| Cayla, R | 1 |
| Zerbib, F | 1 |
| Forestier, S | 1 |
| de Mascarel, A | 1 |
| Joubert-Collin, M | 1 |
| Mégraud, F | 1 |
| Sato, F | 1 |
| Andou, T | 1 |
| Hara, M | 1 |
| Fujinami, T | 1 |
| Suzuki, J | 1 |
| Kobayasi, I | 1 |
| Fujita, T | 1 |
| Kishikawa, H | 1 |
| Kitahora, T | 2 |
| Nagahashi, S | 2 |
| Peddicord, TE | 1 |
| Collier, DS | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| Cianci, R | 1 |
| Cannizzaro, O | 1 |
| Armuzzi, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Cockayne, SE | 1 |
| Glet, RJ | 1 |
| Gawkrodger, DJ | 1 |
| McDonagh, AJ | 1 |
| Kromer, W | 1 |
| Horbach, S | 1 |
| Lühmann, R | 1 |
| Sasakii, M | 1 |
| Yokoyama, Y | 1 |
| Seno, K | 1 |
| Tsuchida, K | 1 |
| Kurokawa, T | 1 |
| Itoh, M | 1 |
| Melnichouk, S | 1 |
| Friendship, RM | 1 |
| Dewey, CE | 1 |
| Bildfell, R | 1 |
| Hirasaki, S | 1 |
| Koide, N | 1 |
| Ogawa, H | 1 |
| Tsuji, T | 1 |
| Sou, Y | 1 |
| Yoshinaga, T | 1 |
| Sekikawa, A | 1 |
| Nakazawa, T | 1 |
| Shio, S | 1 |
| Kohigashi, K | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Yoshida, N | 1 |
| Tanaka, Y | 1 |
| Kassai, K | 1 |
| Naito, Y | 1 |
| Kondo, M | 1 |
| Agrawal, NM | 2 |
| Campbell, DR | 2 |
| Safdi, MA | 1 |
| Lukasik, NL | 2 |
| Haber, MM | 2 |
| Cattoli, G | 1 |
| Bart, A | 1 |
| Klaver, PS | 1 |
| Robijn, RJ | 1 |
| Beumer, HJ | 1 |
| van Vugt, R | 1 |
| Pot, RG | 1 |
| van der Gaag, I | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Kuipers, EJ | 1 |
| Kusters, JG | 1 |
| Kawamura, T | 1 |
| Miyaji, C | 1 |
| Toyabe, S | 1 |
| Abo, T | 1 |
| Ohtsubo, K | 1 |
| Sakai, J | 1 |
| Kawashima, A | 1 |
| Harasawa, S | 1 |
| Nakamura, T | 1 |
| Kajiyama, G | 1 |
| Ogawa, N | 2 |
| Yao, T | 1 |
| Muto, Y | 1 |
| Nakazawa, S | 1 |
| van den Wollenberg, L | 1 |
| Sloet van Oldruitenborgh-Oosterbaan, MM | 1 |
| Gracioso, JD | 1 |
| de Paula, AC | 1 |
| Brasil, DD | 1 |
| Muller, AH | 1 |
| Bardou, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Ikeda, S | 1 |
| Tamamuro, T | 1 |
| Hamashima, C | 1 |
| Graham, DY | 1 |
| Collis, C | 1 |
| Miyazawa, M | 1 |
| Suzuki, K | 1 |
| Adachi, K | 1 |
| Suetsugu, H | 1 |
| Moriyama, N | 1 |
| Kazumori, H | 1 |
| Kawamura, A | 1 |
| Fujishiro, H | 1 |
| Sato, H | 1 |
| Okuyama, T | 1 |
| Ishihara, S | 1 |
| Watanabe, M | 1 |
| Bown, RL | 1 |
| Zlabek, JA | 1 |
| Anderson, CG | 1 |
| Shiraishi, T | 1 |
| Otsubo, T | 1 |
| Nakamura, H | 1 |
| Miyazawa, K | 1 |
| Narushima, K | 1 |
| Matsuoka, T | 1 |
| Astudillo, L | 1 |
| Barradell, LB | 1 |
| McTavish, D | 1 |
| Bergmann, JF | 1 |
| Chassany, O | 1 |
| Simoneau, G | 1 |
| Segrestaa, JM | 1 |
| Caulin, C | 1 |
| Kuwayama, H | 1 |
| Matsuo, Y | 1 |
| Eastwood, GL | 1 |
| Inatomi, N | 1 |
| Nagaya, H | 1 |
| Takami, K | 1 |
| Shino, A | 1 |
| Kubo, K | 1 |
| Kaneko, T | 1 |
| Nohara, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of Bismuth-containing Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection in 10 Days and 14 Days: a Prospective, Randomized, Controlled Study[NCT05586113] | Phase 4 | 398 participants (Anticipated) | Interventional | 2023-02-06 | Not yet recruiting | ||
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis[NCT05005910] | Early Phase 1 | 194 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer[NCT01452724] | Phase 3 | 372 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Gastric Ulcer.[NCT01452711] | Phase 3 | 482 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032] | Phase 3 | 1,045 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
19 reviews available for lansoprazole and Stomach Ulcer
| Article | Year |
|---|---|
Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis.
Topics: Endoscopic Mucosal Resection; Humans; Lansoprazole; Proton Pump Inhibitors; Stomach Neoplasms; Stoma | 2023 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Duodenal | 2013 |
[Treatment of NSAID-associated gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazol | 1994 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
[Lansoprazole--profile of a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1994 |
[Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Helicobacter Infections; Helicobacter pylori; Humans; Lanso | 1993 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Benign gastric ulcer associated with Canidida infection in a healthy adult.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alanine; Anti-Infective Agents; Anti-Ulcer Agents; Candidia | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
[Gastric ulceration in horses: etiology, diagnosis, and therapy: a review].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antacids; Anti-Ulcer Agents; Dose-Response Relatio | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
83 trials available for lansoprazole and Stomach Ulcer
| Article | Year |
|---|---|
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzene Derivatives; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
Topics: Dissection; Endoscopic Mucosal Resection; Humans; Lansoprazole; Prospective Studies; Proton Pump Inh | 2021 |
Comparison of oral and intravenous lansoprazole for the prevention of bleeding from artificial ulcers after endoscopic submucosal dissection for gastric tumors: a prospective randomized phase II study (KDOG 0802).
Topics: Administration, Oral; Aged; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Hemos | 2018 |
Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Lansoprazole; Male; | 2018 |
Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
Topics: Aged; Endoscopic Mucosal Resection; Female; Hematemesis; Hemoglobins; Humans; Lansoprazole; Male; Me | 2019 |
A Multicenter, Randomized, Controlled Trial of Rebamipide Plus Lansoprazole for the Treatment of Postendoscopic Submucosal Dissection Ulcers.
Topics: Administration, Oral; Aged; Alanine; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, C | 2019 |
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
Endoscopic evaluation of low-dose aspirin-induced gastric and duodenal ulcers during prophylaxis with lansoprazole.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Comorbidity; Double-Blind | 2013 |
Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dissection; Drug Administration Schedule; Endosco | 2014 |
The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study.
Topics: Abietanes; Aged; Anti-Ulcer Agents; Dissection; Drug Therapy, Combination; Endoscopy, Gastrointestin | 2015 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lans | 2017 |
Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Critical Illness; Drug Administration Ro | 2008 |
Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2008 |
Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Clarithromycin; D | 2010 |
Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2011 |
Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Drug Administration Sched | 2011 |
Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Female; Gas | 2011 |
Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duod | 2011 |
Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost-Benefit An | 2011 |
Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers: a retrospective analysis and prospective validation study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dissection; Endoscopy, Gastrointestinal; Enzyme Inhib | 2012 |
Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2012 |
Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2013 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alanine; Amoxicillin; Anti- | 2006 |
Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2007 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2007 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Fa | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Jui | 1995 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Anti | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1995 |
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti- | 1995 |
Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Female; Gastric | 1995 |
Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Depression, Chemical; Famot | 1995 |
Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Famotidi | 1995 |
Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastric Mucosa; Gas | 1995 |
Endosonographic evaluation of the quality of ulcer healing induced by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastric Mucosa; Gastroscopy; Histamine H | 1995 |
Effects of lansoprazole on gastric ulcer healing and mucin content.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Depression, Chemical; Femal | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
Quantitative analysis of the gastric ulcer healing process using video endoscopic pseudocolor imaging systems.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Epithelium; Female; Hemoglobins; | 1995 |
Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastric | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Evaluation of gastric ulcer healing by lansoprazole by measurement of ulcer diameter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Cimetidine; Female; G | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Admini | 1995 |
Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1994 |
Rapid healing of gastric ulcers with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1994 |
Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Doubl | 1994 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1993 |
Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Autoradiography; Binding Sites; Biopsy; | 1995 |
A trial of lansoprazole in refractory gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Drug Resistanc | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer | 1996 |
Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer A | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Female; Gastric Muc | 1997 |
Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1997 |
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Cell Count; Double-Blind Method; | 1998 |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1998 |
Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Ulcer Agents; Diterpenes; | 1998 |
Effects of trimebutine maleate on gastric motility in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Drug Therapy, Combination; Enz | 1998 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicob | 1999 |
Evaluation of lansoprazole (an H+/K+-ATPase inhibitor) and azithromycin (an antibiotic) for control of gastric ulceration in swine during periods of feed deprivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animal Feed; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 1999 |
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2000 |
Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug | 2000 |
Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine | 2000 |
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Female; Gastric | 2001 |
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ul | 1992 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Anti-Ulcer Agents; Aspirin; Do | 1992 |
82 other studies available for lansoprazole and Stomach Ulcer
| Article | Year |
|---|---|
Gastroprotective activity of ent-beyerene derivatives in mice: Effects on gastric secretion, endogenous prostaglandins and non-protein sulfhydryls.
Topics: Abietanes; Animals; Anti-Ulcer Agents; Baccharis; Cell Line; Cell Survival; Gastric Juice; Gastric M | 2015 |
Gastroprotective effects of new diterpenoid derivatives from Azorella cuatrecasasii Mathias & Constance obtained using a β-cyclodextrin complex with microbial and chemical transformations.
Topics: Alcohols; Animals; Anti-Ulcer Agents; Apiaceae; beta-Cyclodextrins; Disease Models, Animal; Diterpen | 2016 |
Gastroprotective activity of synthetic coumarins: Role of endogenous prostaglandins, nitric oxide, non-protein sulfhydryls and vanilloid receptors.
Topics: Animals; Anti-Ulcer Agents; Coumarins; Gastric Mucosa; Mice; Nitric Oxide; Prostaglandins; Stomach U | 2016 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Proton Pump Inhibitors Prevent Gastric Antral Ulcers Induced by NSAIDs via Activation of Capsaicin-Sensitive Afferent Nerves in Mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Disease Models, Animal; Gastric Emptyin | 2020 |
Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
Topics: Benzene Derivatives; Humans; Imidazoles; Lansoprazole; Potassium; Stomach Ulcer | 2020 |
The essential oil from Baccharis trimera (Less.) DC improves gastric ulcer healing in rats through modulation of VEGF and MMP-2 activity.
Topics: Acetic Acid; Animals; Anti-Ulcer Agents; Baccharis; Brazil; Caspases; Cyclooxygenase 1; Cyclooxygena | 2021 |
Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
Topics: Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Japan; Lansoprazole; Logistic | 2018 |
Protective effect of coptisine free base on indomethacin-induced gastric ulcers in rats: Characterization of potential molecular mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Berberine; Cyclooxygenase 1; Cyclooxygenase 2; Dise | 2018 |
Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation.
Topics: Animals; Anti-Ulcer Agents; Caco-2 Cells; Gastric Acid; Humans; Intestinal Absorption; Intestinal Mu | 2014 |
Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations.
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Caco-2 Cells; Humans; Lansoprazole; Nanoparticles; | 2015 |
Sticky Palms Following Use of Proton-Pump Inhibitors.
Topics: Administration, Oral; Adult; Drug Eruptions; Esomeprazole; Female; Gastroesophageal Reflux; Hand Der | 2016 |
Effects of vonoprazan on intractable non-steroidal anti-inflammatory drug-induced ulcers that cannot be controlled with conventional proton pump inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lansoprazole; Middle Aged; Proton Pump Inhi | 2017 |
A rare cause of GI bleeding in a 56-year-old man.
Topics: Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Mucormycosi | 2017 |
Inappropriate use of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cross-Sectional Studies; Dyspepsia | 2010 |
Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Ulcer Agents; Cell Cycle; Cell P | 2010 |
Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2011 |
Attenuation of stress-induced gastric lesions by lansoprazole, PD-136450 and ranitidine in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Indoles; Indomethacin; Injec | 2011 |
Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Biomarkers; Cisapride; Disease Models | 2011 |
Gastroprotective effect and cytotoxicity of carnosic acid derivatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Animals; Anti-Ulcer Agents; Antioxidants; Cell L | 2011 |
Gastroprotective activity of epitaondiol and sargaol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Ethanol; Hydrochloric Acid; Lan | 2011 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cy | 2013 |
[Effect of various antisecretory drugs on morphological changes in rat gastric mucosa in experimental stomach ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Epithelium; Famotidine; Gastric | 2002 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2002 |
A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antioxidants; Apoptosis; DNA Damage; Free Radical | 2003 |
[Is gastric and duodenal ulcer drug-treatable or surgical disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Om | 1997 |
Gastric myoelectrical activity in patients with recurrent gastric or duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Digest | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 2003 |
Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cyclooxygenase 1; Cyclooxygenas | 2004 |
Gastric antiulcer activity of Syngonanthus arthrotrichus SILVEIRA.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bethanechol; Cimetidine; Diseas | 2004 |
Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Female; Fibroblast Growth Factor | 2004 |
[Chronic upper abdominal pain without improvement after using proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Ulcer Agents; Azathioprine; Duodenal U | 2004 |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Colony Count, Mic | 2004 |
Gastroprotective activity of a new semi-synthetic solidagenone derivative in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Anti-Ulcer Agents; Cell Line | 2005 |
Mechanisms of action of leptin in preventing gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Lansoprazole; Leptin; Nitric Ox | 2005 |
Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Diagnosis, Differential; Female; Humans; Lansoprazole | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
Gastroprotective and ulcer-healing activity of oleanolic acid derivatives: in vitro-in vivo relationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cell Line; Cell Proliferation; | 2006 |
Endoplasmic reticulum stress response is involved in the pathogenesis of stress induced gastric lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Apoptosis; Caspase 12; Caspases; Disease Models, A | 2006 |
Constituents and antiulcer effect of Alchornea glandulosa: activation of cell proliferation in gastric mucosa during the healing process.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Cell Proliferation; D | 2007 |
Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2007 |
Epstein-Barr virus gastritis: an underrecognized form of severe gastritis simulating gastric lymphoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Diagnosis, Differential; Endoscopy, | 2007 |
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Animals; Anti-Ulcer Agents; Antioxidants; Catalas | 2007 |
[Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2008 |
Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Dru | 1995 |
Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anesthesia; Animals; Anti-Ulcer Agents; Cats; Female; Gastr | 1995 |
Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa.
Topics: 16,16-Dimethylprostaglandin E2; 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory | 1995 |
Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Resistance; Duodenal Ulcer; Gastric | 1995 |
Factors affecting quality of ulcer healing after lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Alcohol Drinking; Anti-Ulcer Agents; Duodenal | 1995 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy | 1995 |
Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Electronics, Medical; Famot | 1995 |
Endoscopic ultrasonographic evaluation of gastric ulcer healing on treatment with proton pump inhibitors versus H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastros | 1994 |
Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Helicobacter Infections; He | 1993 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; | 1997 |
[A case of hemolysis induced by lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anemia, Hemolytic; Anti-Ulcer Agents; Humans; Lansoprazole; | 1996 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studi | 1998 |
Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chem | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Effect of combined administration of lansoprazole and sofalcone on microvascular and connective tissue regeneration after ethanol-induced gastric mucosal damage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; CD36 Antigens; Chalcone; Chalco | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; | 1998 |
Effect of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of mononuclear cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Critical Care; DNA; Histamine H2 Antagon | 1999 |
Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dermatitis, Exfoliative; Drug Erup | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cel | 2000 |
Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2000 |
Suppressive effect of antiulcer agents on granulocytes--a role for granulocytes in gastric ulcer formation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Animals; Anti-Ulcer Agents; Depression, Chemical; Gr | 2000 |
Evaluation of the gastroprotective activity of cordatin, a diterpene isolated from Aparisthmium cordatum (Euphorbiaceae).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Disease Models, Animal; Diterpe | 2000 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
A comparative study on the activity of lansoprazole, omeprazole and PD-136450 on acidified ethanol- and indomethacin-induced gastric lesions in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Central N | 2002 |
Lansoprazole-induced thrombocytopenia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Gastrointestina | 2002 |
[Treatment of NSAIDs induced ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
Gastroprotective activity of oleanolic acid derivatives on experimentally induced gastric lesions in rats and mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Aspirin; Dose-Response Relation | 2002 |
[H2-receptor antagonist-refractory ulcer--its pathophysiology and role of proton-pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Depression, Chemical; D | 1992 |
Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Acetic Acid; Animals; Anti-Ulcer Agents; Cimetidi | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as antiulcer agents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cell Survival; Gastric Mucosa; | 1990 |